Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8897329 | 1.00 | ALDH1A1 (0.33) | ALDH1A1KDM4EHSD17B10GAAPKM | |
| SCHEMBL8947056 | 0.74 | ALDH1A1 (0.35) | ALDH1A1KDM4EHSD17B10GAAPKM | |
| SCHEMBL8947051 | 0.74 | ALDH1A1 (0.35) | ALDH1A1KDM4EHSD17B10GAAPKM | |
| SCHEMBL13698843 | 0.74 | ALDH1A1 (0.35) | ALDH1A1KDM4EHSD17B10GAAPKM | |
| SCHEMBL25971659 | 0.67 | — | — | |
| SCHEMBL20109314 | 0.67 | KDM4E (0.30) | ALDH1A1KDM4EHSD17B10GAAPKM | |
| SCHEMBL19367682 | 0.67 | KDM4E (0.30) | ALDH1A1KDM4EHSD17B10GAAPKM | |
| SCHEMBL25971758 | 0.66 | GAA (0.30) | GAAPKMTDP1 | |
| SCHEMBL25971787 | 0.66 | GAA (0.30) | GAAPKMTDP1 | |
| SCHEMBL25971812 | 0.66 | GAA (0.30) | GAAPKMTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5618964-A | Prodrug esters of phosphonosulfonate squalene synthetase inhibitors and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-04-08 | — | — | US | disclosed |
| US-5470845-A | Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-11-28 | — | — | US | disclosed |
| EP-0595635-A1 | Alpha-phosphorous substituted sulfonate derivatives as squalene synthetase inhibitors | E.R. Squibb & Sons, Inc. (US) | 1994-05-04 | — | — | EP | disclosed |